What is Zymeworks's exchange offer (note 12)?

Zymeworks (ZYME) reported exchange offer (note 12) of $0 in Q1 2026.

What does exchange offer (note 12) mean?

The aggregate value of equity instruments converted into common stock during the period. This captures the financial impact of equity-linked instruments being exercised or converted, providing insight into potential shareholder dilution and changes in the company's equity base.

Zymeworks ZYME Exchange Offer (Note 12)

Exchange Offer (Note 12) at other companies

MacerichMAC

$5.23M+4,335%

Oruka Therapeutics, Inc.ORKA

$52.83M—

Quantum Computing Inc.QUBT

$1.02M+687,316%

Iovance Biotherapeutics, Inc.IOVA

$1K—

ServiceTitan, Inc.TTAN

$348.97K—

Sionna Therapeutics, Inc. Common StockSION

$0-100%

Other financials

Income statement

See full

Revenue$2.4M-91.1%

Operating income-$47.1M-84.0%

Net income-$44.2M-95.1%

EPS (diluted)-$0.59-96.7%

Balance sheet

See full

Cash & equivalents$244.3M+221%

Total debt$17.0M-7.7%

Total equity$163.6M-49.7%

Total assets$478.2M+12.4%

Cash flow

See full

Operating cash flow-$45.7M-1,242%

CapEx$216.0K+1,250%

Free cash flow-$45.9M-1,242%

Valuation

See full

Market cap$1.76B+125%

Enterprise value$1.53B+112%

P/S21.6×+13.2×

Profitability

See full

Operating margin-140.4%+7.3pp

Net margin-126.3%+5.0pp

FCF margin-94.8%+15.5pp

Returns & leverage

See full

Return on equity-42%+29.2pp

Debt / equity0.1×0.0×

Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:ConversionOfStockAmountConverted1.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's exchange offer (note 12).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Zymeworks's exchange offer (note 12)?: Zymeworks (ZYME) reported exchange offer (note 12) of $0 in Q1 2026.
What does exchange offer (note 12) mean?: The aggregate value of equity instruments converted into common stock during the period. This captures the financial impact of equity-linked instruments being exercised or converted, providing insight into potential shareholder dilution and changes in the company's equity base.